Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

82.95USD
3:59pm EST
Change (% chg)

$0.07 (+0.08%)
Prev Close
$82.88
Open
$82.88
Day's High
$83.64
Day's Low
$82.65
Volume
423,833
Avg. Vol
457,919
52-wk High
$100.50
52-wk Low
$79.51

Select another date:

Thu, Oct 26 2017

BRIEF-Biomarin reports Q3 loss $0.07/shr

* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

BRIEF-Biomarin Pharmaceutical: Increased board size from nine to ten members​

* Biomarin Pharmaceutical says ‍on September 28, 2017, board of directors of increased size of board from nine to ten members​ - SEC filing Source: (http://bit.ly/2yWOHiP) Further company coverage:

BRIEF-FDA not planning to hold advisory committee meeting for Biomarin's Pegvaliase BLA

* FDA not currently planning to hold advisory committee meeting for Biomarin's Pegvaliase Biologics License Application (BLA)

BRIEF-FDA accepts Biomarin's Pegvaliase Biologics License Application

* FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation

BRIEF-BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes

* BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024

BRIEF-Biomarin announces offering of $450 mln of senior subordinated convertible notes due 2024

* Biomarin announces offering of $450 million of senior subordinated convertible notes due 2024

BRIEF-BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational gene therapy for Hemophilia A, into phase 3 studies

* BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational Gene Therapy For Hemophilia A, into phase 3 studies

BRIEF-Sarepta and Biomarin report execution of global settlement

* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation

BRIEF-Biomarin Pharmaceutical says plans to initiate phase 3 registrational study in Q4 2017 for BMN 270

* Biomarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg dose maintains average factor VIII levels within normal range for over one year

Select another date: